Acute liver failure diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
 
(5 intermediate revisions by 3 users not shown)
Line 4: Line 4:
{{Acute liver failure}}
{{Acute liver failure}}
== Overview ==
== Overview ==
Acute liver failure is a sudden loss of [[hepatic]] function in a patient without any evidence of underlying liver disease. The diagnosis of acute liver failure is made in the presence of [[coagulopathy]] (international normalized ratio [INR], >1.5), [[hepatic encephalopathy]] and illness duration of fewer than 24 weeks.
Acute liver failure is a sudden loss of [[hepatic]] function in a patient without any evidence of underlying liver disease. Acute liver failure should be suspected in a patient with mental status changes, [[jaundice]], and [[right upper quadrant pain]] or nonspecific symptoms such as [[malaise]], [[nausea]] and [[fatigue]] of fewer than 26 weeks. The further evaluation should include [[liver function tests]] ([[AST|aspartate aminotransferase [AST]]], [[ALT|alanine aminotransferase [ALT]]], [[alkaline phosphatase]], [[Gamma-glutamyl transpeptidase|gamma-glutamyl transpeptidase [GGT]]], total and direct [[bilirubin]], [[albumin]]) and [[Prothrombin time (PT)|prothrombin time/INR]]. The diagnosis of acute liver failure is made in the presence of [[coagulopathy]] ([[international normalized ratio]] ([[INR]]), >1.5), [[hepatic encephalopathy]] and illness duration of fewer than 24 weeks.
 
== Diagnostic Criteria ==
== Diagnostic Criteria ==
* Acute liver failure is a sudden loss of [[hepatic]] function in a patient without any evidence of underlying liver disease.<ref name="pmid18318440">{{cite journal| author=Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH| title=Acute liver failure: Summary of a workshop. | journal=Hepatology | year= 2008 | volume= 47 | issue= 4 | pages= 1401-15 | pmid=18318440 | doi=10.1002/hep.22177 | pmc=3381946 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18318440  }} </ref>
* Acute liver failure is a sudden loss of [[hepatic]] function in a patient without any evidence of underlying liver disease.<ref name="pmid18318440">{{cite journal| author=Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH| title=Acute liver failure: Summary of a workshop. | journal=Hepatology | year= 2008 | volume= 47 | issue= 4 | pages= 1401-15 | pmid=18318440 | doi=10.1002/hep.22177 | pmc=3381946 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18318440 }} </ref><ref name="pmid23439263">{{cite journal| author=Bernal W, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJ, Auzinger G et al.| title=Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. | journal=J Hepatol | year= 2013 | volume= 59 | issue= 1 | pages= 74-80 | pmid=23439263 | doi=10.1016/j.jhep.2013.02.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23439263  }} </ref><ref name="pmid22506515">{{cite journal| author=Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA| title=Systematic review: acute liver failure - one disease, more than 40 definitions. | journal=Aliment Pharmacol Ther | year= 2012 | volume= 35 | issue= 11 | pages= 1245-56 | pmid=22506515 | doi=10.1111/j.1365-2036.2012.05097.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22506515 }} </ref>
* Acute liver failure should be suspected in a patient with mental status changes, [[jaundice]], and right upper quadrant pain or nonspecific symptoms such as [[malaise]], nausea and fatigue of fewer than 26 weeks. The further evaluation should include [[liver function tests]] ([[AST|aspartate aminotransferase [AST]]], [[ALT|alanine aminotransferase [ALT]]], [[alkaline phosphatase]], [[Gamma-glutamyl transpeptidase|gamma-glutamyl transpeptidase [GGT]]], total and direct [[bilirubin]], albumin) and [[Prothrombin time (PT)|prothrombin time/INR]].
* Acute liver failure should be suspected in a patient with mental status changes, [[jaundice]], and [[right upper quadrant pain]] or nonspecific symptoms such as [[malaise]], [[nausea]] and [[fatigue]] of fewer than 26 weeks. The further evaluation should include [[liver function tests]] ([[AST|aspartate aminotransferase [AST]]], [[ALT|alanine aminotransferase [ALT]]], [[alkaline phosphatase]], [[Gamma-glutamyl transpeptidase|gamma-glutamyl transpeptidase [GGT]]], total and direct [[bilirubin]], [[albumin]]) and [[Prothrombin time (PT)|prothrombin time/INR]].
* The diagnosis of acute liver failure is made in the presence of:
* The diagnosis of acute liver failure is made in the presence of:
** [[Coagulopathy]] ([[INR|International normalized ratio [INR]]], >1.5)
** [[Coagulopathy]] ([[INR|International normalized ratio [INR]]] > 1.5)
** [[Hepatic encephalopathy]]
** [[Hepatic encephalopathy]]
** Illness duration of fewer than 24 weeks
** Illness duration of fewer than 24 weeks
==References==
==References==
<references />
{{Reflist|2}}

Latest revision as of 20:57, 18 December 2017


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Acute liver failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute Liver Failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute liver failure diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute liver failure diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute liver failure diagnostic study of choice

CDC on Acute liver failure diagnostic study of choice

Acute liver failure diagnostic study of choice in the news

Blogs on Acute liver failure diagnostic study of choice

Directions to Hospitals Treating Acute liver failure

Risk calculators and risk factors for Acute liver failure diagnostic study of choice

Overview

Acute liver failure is a sudden loss of hepatic function in a patient without any evidence of underlying liver disease. Acute liver failure should be suspected in a patient with mental status changes, jaundice, and right upper quadrant pain or nonspecific symptoms such as malaise, nausea and fatigue of fewer than 26 weeks. The further evaluation should include liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin) and prothrombin time/INR. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio (INR), >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks.

Diagnostic Criteria

References

  1. Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH (2008). "Acute liver failure: Summary of a workshop". Hepatology. 47 (4): 1401–15. doi:10.1002/hep.22177. PMC 3381946. PMID 18318440.
  2. Bernal W, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJ, Auzinger G; et al. (2013). "Lessons from look-back in acute liver failure? A single centre experience of 3300 patients". J Hepatol. 59 (1): 74–80. doi:10.1016/j.jhep.2013.02.010. PMID 23439263.
  3. Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA (2012). "Systematic review: acute liver failure - one disease, more than 40 definitions". Aliment Pharmacol Ther. 35 (11): 1245–56. doi:10.1111/j.1365-2036.2012.05097.x. PMID 22506515.